GPR132 antagonists alleviate atherosclerosis by suppressing M1 polarization and subsequent VSMCs proliferation and migration as revealed by transcriptomic profiling
Mechanistically, GPR132 drove M1 macrophage polarization primarily through activation of the p38/MAPK signaling pathway, an effect reversible by SB203580 or GPR132 antagonists, and its antagonism mitigates atherosclerotic progression by suppressing inflammatory microenvironments and VSMCs proliferation/migration.